Back to the Top
Requirements for BE study of a new molecule not approved in India but approved in the other countries includes
Pre-clinical single dose data and repeated dose toxicity data.
My doubt is in these preclinical testings the results of the test formulation are to be compared with the reference formulation or with vehicle control.
Thanks In anticipation
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Toxicity for Bioequivalent" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (email@example.com)